Related Experiment Video

Updated: Apr 11, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

927

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia

Lars Fransecky1, Liliana H Mochmann1, Claudia D Baldus1

  • 1Department of Hematology and Oncology, Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany.

Molecular and Cellular Therapies
|June 10, 2015
PubMed

Insights

Targeting the PI3K/AKT/mTOR pathway shows promise for acute leukemia treatment. High-throughput data reveals upstream mutations driving aberrant activation, identifying specific patient subgroups for therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • High-throughput analyses advance cancer signaling understanding.
  • The PI3K/AKT/mTOR pathway is central to cancer growth, survival, and metabolism.
  • Mutations in this pathway are frequent across cancer types, driving therapeutic interest.

Purpose of the Study:

  • To review key findings on aberrant PI3K/AKT/mTOR activation in acute leukemia.
  • To discuss the potential and challenges of targeting this pathway in acute leukemia.
  • To highlight how high-throughput data can identify specific acute leukemia subgroups for targeted therapy.

Main Methods:

  • Review of existing literature and high-throughput data.
  • Analysis of genetic mutations and signaling pathway activation.
  • Identification of upstream and downstream targets within the PI3K/AKT/mTOR pathway.

Main Results:

  • While direct PI3K/AKT/mTOR mutations are rare in acute leukemia, upstream mutations frequently cause pathway activation.
  • Aberrant PI3K/AKT/mTOR signaling is a key feature in certain acute leukemias.
  • High-throughput data provides insights into patient stratification for targeted therapies.

Conclusions:

  • Targeting PI3K/AKT/mTOR in acute leukemia presents challenges due to absent downstream mutations.
  • Upstream genetic alterations offer a rationale for exploring PI3K/AKT/mTOR inhibition.
  • Personalized medicine approaches using high-throughput data can optimize PI3K/AKT/mTOR targeted therapy efficacy in acute leukemia.
Keywords:
AKTAcute leukemiaPI3KTargeted therapymTOR

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K